Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
prnewswire.com     May 23, 2008            

CALGARY, May 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced it has been granted Canadian Patent 2,360,833 entitled "Reovirus for the Treatment of Cellular Proliferative Disorders." The claims describe the use of one or more recombinant... [read full story]                    


View all news articles about*:
Alberta America Biotech Biotechnology Calgary Canada Cancer Cancers Corporate Industrial Intellectual Issues Legal North Oncolytics Patents Pharmaceuticals Property Therapy
*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

View other selected articles:

Oncolytics initiates US Phase II lung cancer trial

pharmaceutical-business-review.com     Sep 3, 2008   5 related          

Oncolytics Biotech has announced that following the FDA review, the company is initiating a US Phase II clinical trial using intravenous administration of Reolysin in combination with paclitaxel and carboplatin in patients...                    

comments

US NCI initiates Phase II enrollment for Reolysin

pharmaceutical-business-review.com     Aug 16, 2008   4 related          

Oncolytics Biotech has announced that the US National Cancer Institute, part of the National Institutes of Health, has started enrollment in a Phase II clinical trial for patients with metastatic melanoma using systemic...                    

comments

U.S. NCI Starts Enrolment In Phase 2 Systemic Melanoma Clinical Trial With REOLYSIN(R)

medicalnewstoday.com     Aug 13, 2008   9 related          

Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that the U.S. National Cancer Institute (NCI), part of the National Institutes of Health, has started enrolment in a Phase 2 clinical trial for patients...                    

comments

U.S. Patent Disclosures

tmcnet.com     Jul 31, 2008          

of Halle, Germany, received U.S. Patent No. 7,371,404, titled "Amphoteric liposomes and their use." Oncolytics Biotech Inc., of Calgary, Alberta, was granted U.S. Patent No. 7,374,752, titled "Reovirus for the Treatment of...                    

comments